Detalhe da pesquisa
1.
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway.
Cell
; 187(11): 2717-2734.e33, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653239
2.
Gut bacteria alleviate smoking-related NASH by degrading gut nicotine.
Nature
; 610(7932): 562-568, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261549
3.
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
J Hepatol
; 80(6): 913-927, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340812
4.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol
; 80(3): 419-430, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984709
5.
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Hepatology
; 78(1): 195-211, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36924031
6.
The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
Liver Int
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578141
7.
Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning.
Liver Int
; 44(2): 330-343, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38014574
8.
Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
Liver Int
; 44(3): 749-759, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38131420
9.
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
Liver Int
; 44(5): 1129-1141, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426611
10.
LNCHC directly binds and regulates YBX1 stability to ameliorate metabolic dysfunction-associated steatotic liver disease progression.
Liver Int
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38847599
11.
Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction-associated fatty liver disease: An exploratory study.
Diabetes Obes Metab
; 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38874096
12.
Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Arterioscler Thromb Vasc Biol
; 43(3): 482-491, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727522
13.
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
JAMA
; 331(15): 1287-1297, 2024 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512249
14.
Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice.
J Biol Chem
; 298(6): 101946, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35447114
15.
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
J Hepatol
; 78(2): 247-259, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375686
16.
aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients.
Clin Gastroenterol Hepatol
; 21(12): 3070-3079.e13, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36933605
17.
Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
Clin Gastroenterol Hepatol
; 21(12): 3097-3106.e10, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031715
18.
Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor.
Hepatology
; 76(6): 1794-1810, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35586979
19.
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
Hepatology
; 76(4): 1105-1120, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35152446
20.
Novel urinary protein panels for the non-invasive diagnosis of non-alcoholic fatty liver disease and fibrosis stages.
Liver Int
; 43(6): 1234-1246, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36924436